48 related articles for article (PubMed ID: 7806087)
1. Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Haematologica; 1994; 79(4):328-33. PubMed ID: 7806087
[TBL] [Abstract][Full Text] [Related]
2. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.
Shudo N; Mizoguchi T; Kiyosue T; Arita M; Yoshimura A; Seto K; Sakoda R; Akiyama S
Cancer Res; 1990 May; 50(10):3055-61. PubMed ID: 1970752
[TBL] [Abstract][Full Text] [Related]
3. Lacidipine and josamycin: two new multidrug resistance modulators.
Crosta L; Candiloro V; Meli M; Tolomeo M; Rausa L; Dusonchet L
Anticancer Res; 1994; 14(6B):2685-9. PubMed ID: 7872702
[TBL] [Abstract][Full Text] [Related]
4. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Dietel M; Boss H; Reymann A; Pest S; Seidel A
J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
[TBL] [Abstract][Full Text] [Related]
5. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
6. Iodination increases the activity of verapamil derivatives in reversing PGP multidrug resistance.
Barattin R; Gerby B; Bourges K; Hardy G; Olivares J; Boutonnat J; Arnoult C; D'Hardemare AD; Ronot X
Anticancer Res; 2010 Jul; 30(7):2553-9. PubMed ID: 20682982
[TBL] [Abstract][Full Text] [Related]
7. Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line.
Tasaki Y; Nakagawa M; Ogata J; Kiue A; Tanimura H; Kuwano M; Nomura Y
J Urol; 1995 Sep; 154(3):1210-6. PubMed ID: 7637090
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.
Miri R; Mehdipour A
Bioorg Med Chem; 2008 Sep; 16(18):8329-34. PubMed ID: 18701304
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
[TBL] [Abstract][Full Text] [Related]
11. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study on effect of two bisbenzylisoquinolines, tetrandrine and berbamine, on reversal of multidrug resistance].
Tian H; Pan QC
Yao Xue Xue Bao; 1997 Apr; 32(4):245-50. PubMed ID: 11499024
[TBL] [Abstract][Full Text] [Related]
13. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Zhou XF; Zhang L; Tseng E; Scott-Ramsay E; Schentag JJ; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):321-8. PubMed ID: 15585608
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
15. Combined Fourier transform infrared and Raman spectroscopic approach for identification of multidrug resistance phenotype in cancer cell lines.
Krishna CM; Kegelaer G; Adt I; Rubin S; Kartha VB; Manfait M; Sockalingum GD
Biopolymers; 2006 Aug; 82(5):462-70. PubMed ID: 16493658
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
17. Selection of a new multidrug resistant cell line from Friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin.
Abbadessa V; Tolomeo M; Luparello M; Perricone R; Cajozzo A; Dusonchet L; Candiloro V; Crosta L; Rausa L
Haematologica; 1992; 77(2):137-41. PubMed ID: 1356894
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
19. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
